The Bias Brief

Lean

Washington ExaminerSep 21, 2026Sig. 6OpinionHealth Economy Trade

Trump’s drug price plan targets foreign freeloaders — but shoots American innovators

An op-ed argues that the Trump administration’s GLOBE and GUARD Medicare pilot programs, meant to stop foreign free-riding on U.S. drug prices, would instead penalize small and mid-size American biotech firms. Because those firms often out-license foreign marketing rights, the piece says they cannot control foreign pricing and would bear costs they cannot recover, potentially reducing innovation and patient access. It urges the administration to confront foreign governments directly rather than penalize U.S. innovators.

Daily MailSep 21, 2026Sig. 4NewsHealth Science

How to avoid CANCER, by Britain's top doctors - including the exact amount of sex you should be having, the store cupboard staple to use instead of sugar and why you must wear suncreen for a MANICURE

A health feature compiles cancer-prevention habits from UK oncologists, covering diet, exercise, supplements, blood sugar monitoring, and screening. It offers practical lifestyle advice without political or ideological framing.

Neutral

Daily MailSep 21, 2026Sig. 4NewsHealth

Pensioner is forced to have both legs amputated after medics took 29 appointments to diagnose common condition

An 80-year-old man underwent double leg amputation after it took 29 appointments over four years to diagnose peripheral arterial disease. His wife says the delay was 'disgraceful' and that a simple Doppler test could have saved his legs, with the NHS spending over £1 million on his care.

Right 2.6

Fox NewsSep 21, 2026Sig. 5OpinionHealth Economy Trade

If Trump wants to lower drug prices, his obvious free-riding targets are outside the US

This opinion piece argues that Trump's new drug pricing agreements are commendable but insufficient because the root cause of high U.S. drug prices is foreign governments free-riding on American pharmaceutical innovation. It urges the administration to target foreign price controls and rebate policies so other wealthy nations pay more for medicines.

Right 3.6